Highlights


Revenue $156.6m

FY15 $125.0m

Up 25.3% on pcp

NPAT $28.8m

FY15 $21.4m

Up 34.6% on pcp

EBITDA $49.6m

FY15 $38.8m
Up 27.6% on pcp

Cash Conversion1 99.1%

FY15 103.3%
Down 4.1% on pcp

Total FY16 Dividend 8.5c

FY15 6.95 cents
Up 22.3% on pcp

Basic EPS 12.2c

FY15 9.2 cents
Up 32.6% on pcp

 

 $m FY16  FY15  % change
 Group revenues  $156.6  $125.0  25.3%
 EBITDA  $49.6  $38.8  27.6%
 EBIT  $45.4  $35.4  28.1%
 NPAT  $28.8  $21.4  34.6%
 EPS (cents)  12.2  9.2  32.6%
 DPS (cents)  8.50  6.95  22.3%
 Cash Inflow from Operations  $44.2  $36.0  22.8%
 Net Debt  $86.5  $96.8
 Net Debt to Equity ratio(1)  55.9%  67.2%
 Return on Equity (pa.)(2)  19.3%  15.9%

(1)    Net Debt to Equity is calculated using Net Debt divided by equity as at 30 June 2016.
(2)    Return on Equity is calculated using NPAT for the previous 12 month period divided by the average equity in the same period.

 

Track record  of strong financial performance

Number of Patient Treatments1
3 year CAGR3 of 12.5%
EBITDA ($m)2
3 year CAGR3 of 12.4%
 no_of_patients_animate_v2 ebitda_graph_anime_v3

Revenue ($m)

3 year CAGR3 of 17.6%

NPAT ($m)2

3 year CAGR3 of 16.3%
revenue_graph_animate_v2 npat_graph_animate_v2

Notes:

  1. Patient Treatments are the sum of fresh and cancelled cycles and frozen embryo transfers.
  2. FY13 re-stated to results in June 2014 Prospectus. FY14 adjusted to exclude IPO costs and restructuring costs
  3. CAGR is Compound Annual Growth Rate
  4. FY15 earnings were impacted unfavourably by below industry trend growth rates and one off start up and acquisition costs of $2.5m, (Pre-tax).